MX2019009500A - Anticuerpos anti factor de coagulación xi. - Google Patents

Anticuerpos anti factor de coagulación xi.

Info

Publication number
MX2019009500A
MX2019009500A MX2019009500A MX2019009500A MX2019009500A MX 2019009500 A MX2019009500 A MX 2019009500A MX 2019009500 A MX2019009500 A MX 2019009500A MX 2019009500 A MX2019009500 A MX 2019009500A MX 2019009500 A MX2019009500 A MX 2019009500A
Authority
MX
Mexico
Prior art keywords
antibody
coagulation factor
fxia
fxi
diseases
Prior art date
Application number
MX2019009500A
Other languages
English (en)
Inventor
Wang Wenyi
Yu Quan
Liu Xiaowu
Original Assignee
Shanghai Benemae Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Benemae Pharmaceutical Corp filed Critical Shanghai Benemae Pharmaceutical Corp
Publication of MX2019009500A publication Critical patent/MX2019009500A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen anticuerpos de los mismos que se unen al factor de coagulación XI (FXI) y/o su factor Xla de forma activada (FXIa), o a un fragmento de FXI y/o FXla, y composiciones que contienen los anticuerpos. También se describen métodos para preparar los anticuerpos y el uso de los anticuerpos para tratar y/o prevenir afecciones asociadas a la coagulación tales como trombosis y complicaciones o afecciones asociadas con la trombosis.
MX2019009500A 2017-02-10 2017-12-29 Anticuerpos anti factor de coagulación xi. MX2019009500A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710073984.XA CN108409863B (zh) 2017-02-10 2017-02-10 抗凝血因子xi抗体
PCT/CN2017/119856 WO2018145533A1 (zh) 2017-02-10 2017-12-29 抗凝血因子xi抗体

Publications (1)

Publication Number Publication Date
MX2019009500A true MX2019009500A (es) 2020-01-30

Family

ID=63107934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009500A MX2019009500A (es) 2017-02-10 2017-12-29 Anticuerpos anti factor de coagulación xi.

Country Status (9)

Country Link
EP (1) EP3581587A4 (es)
JP (1) JP7271430B2 (es)
KR (1) KR20190116990A (es)
CN (1) CN108409863B (es)
AU (1) AU2017397778A1 (es)
BR (1) BR112019016300A2 (es)
CA (1) CA3054322A1 (es)
MX (1) MX2019009500A (es)
WO (1) WO2018145533A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11958911B2 (en) 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
CN116554334A (zh) * 2018-08-09 2023-08-08 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
CN110878123B (zh) * 2018-09-05 2022-08-23 华瑞同康生物技术（深圳）有限公司 一种抗tk1原核重组单链抗体及制备方法
WO2020211674A1 (zh) * 2019-04-16 2020-10-22 四川科伦博泰生物医药股份有限公司 抗FXI/FXIa抗体及其用途
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
CN110498839A (zh) * 2019-09-19 2019-11-26 河南省农业科学院 氟罗沙星单链抗体关键多肽序列及应用
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
BR112022026533A2 (pt) * 2020-07-02 2023-01-17 Beijing Tuo Jie Biopharmaceutical Co Ltd Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
CN116589588B (zh) * 2023-04-14 2023-12-22 北京基科晟斯医药科技有限公司 结合凝血因子x的抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2981754B2 (ja) * 1990-02-02 1999-11-22 第一化学薬品株式会社 血液凝固第▲ｘ▼▲ｉｉｉ▼因子に対するモノクロナール抗体
WO2002101040A1 (en) * 2001-06-12 2002-12-19 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human-type anti-blood coagulation factor viii antibody
DE10205520A1 (de) * 2002-02-08 2003-08-14 Aventis Behring Gmbh Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
ES2566963T3 (es) * 2007-11-21 2016-04-18 Oregon Health & Science University Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
DK2373691T3 (en) * 2008-12-18 2019-04-15 Oregon Health&Science Univ ANTI-FXI ANTIBODIES AND PROCEDURES FOR USE
HUE040580T2 (hu) * 2012-05-10 2019-03-28 Bayer Pharma AG XI. véralvadási faktorhoz és/vagy XIA aktivált alakjához kötõdni képes ellenanyagok és alkalmazásuk
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
CA3025896A1 (en) * 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof

Also Published As

Publication number Publication date
EP3581587A4 (en) 2021-03-31
CN108409863B (zh) 2023-09-26
CA3054322A1 (en) 2018-08-16
JP2020507578A (ja) 2020-03-12
AU2017397778A1 (en) 2019-10-03
RU2019128423A3 (es) 2021-03-19
WO2018145533A1 (zh) 2018-08-16
KR20190116990A (ko) 2019-10-15
RU2019128423A (ru) 2021-03-10
CN108409863A (zh) 2018-08-17
JP7271430B2 (ja) 2023-05-11
EP3581587A1 (en) 2019-12-18
BR112019016300A2 (pt) 2020-06-16

Similar Documents

Publication Publication Date Title
MX2019009500A (es) Anticuerpos anti factor de coagulación xi.
WO2018089508A3 (en) Anti-cd47 antibodies
MX2018005720A (es) Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
MX2018009581A (es) Inmunoglobulina con fabs en tandem y sus usos.
NZ738008A (en) Tigit-binding agents and uses thereof
WO2018031490A3 (en) Anti-ox40 binding proteins
NZ727020A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
MX2016011295A (es) Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MY192532A (en) Liquid pharmaceutical composition
WO2017049038A3 (en) Anti-cd115 antibodies
MX2021001613A (es) Anticuerpos anti-factor xi.
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
ZA201900070B (en) Antibodies with low immunogenicity and uses thereof
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
TW201713686A (en) Methods for preparing modified von Willebrand factor
MX2017005522A (es) Tratamiento novedoso de la cornea usando laminina.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
PH12018501277A1 (en) Corticosteroid containing foam compositions and method of manufacture thereof
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
SG11201907914QA (en) Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
MX2019014291A (es) Metodo de tratamiento.